Table 4.

Salivary concentrations according to anti-hypertensive treatments.

	Diuretics		Beta-blockers		Calcium blockers		ACEi or anti-AT1
	No	Yes	No	Yes	No	Yes	No	Yes
N	177	64	190	51	207	34	151	90
Age	64 ± 10	70 ± 9∗∗∗	65 ± 10	69 ± 8∗∗∗	65 ± 10	70 ± 9∗∗	63 ± 10	70 ± 9∗∗∗
Women	30%	33%	30%	31%	33%	15%∗	32%	27%
Sodium (mM)	14.9 (12.1–19.3)	15.4 (12.9–19.2)	14.8 (12.0–17.7)	16.8 (13.7–22.0)∗∗	15.2 (12.3–19.45)	14.9 (11–7-17.6)	14.9 (12.0–19.8)	15.3 (12.6–17.9)
Potassium (mM)	30.3 (25.4–36.2)	34.2 (26.7–40.0)∗	30.1 (25.4–36.0)	34.9 (29.3–42.7)∗∗	31.3 (25.4–36.2)	31.2 (26.4–45.0)	31.02 (25.3–36.4)	31.7 (26.0–37.8)
Calcium (mM)	0.30 (0.24–0.39)	0.32 (0.25–0.43)	0.29 (0.24–0.39)	0.35 (0.27–0.43)∗∗	0.30 (0.24–0.39)	0.32 (0.26–0.49)	0.30 (0.24–0.39)	0.31 (0.25–0.42)
Phosphate (mM)	6.55 (5.22–8.92)	7.16 (5.09–9.42)	6.49 (5.09–8.82)	7.26 (5.71–9.94)	6.58 (5.13–8.77)	6.67 (5.33–11.96)∗	6.46 (5.13–9.05)	6.69 (5.25–8.80)

Data are expressed as either mean ± SD or median (interquartile range) for normally and nonnormally distributed data, respectively. Statistically significant differences were determined using either a Student's t-test (normally distributed data) or Wilcoxon signed-rank test (nonnormally distributed data) for continuous variable. A chi-square test was used for categorical data. ^∗ P < 0.05; ^∗∗ P < 0.01; ^∗∗ P < 0.001 vs. no treatment.